ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EHP Epistem

85.00
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Epistem LSE:EHP London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 85.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
  -
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 85.00 GBX

Epistem (EHP) Latest News

Real-Time news about Epistem (London Stock Exchange): 0 recent articles

Epistem (EHP) Discussions and Chat

Epistem (EHP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Epistem (EHP) Top Chat Posts

Top Posts
Posted at 31/3/2016 07:57 by azzi
More smoke and mirror`s!!
So the Indian Tb launch has been delayed! ..."and the delay in developing sales of Genedrive(R) and associated TB tests in India". They are only now embarking on "launch training" with their distribution partner - what the hell of they been doing for the last three years? I remain concerned that there are still problems with the Genedrive technology, they are claiming validation in some testing centers, however this is a bare minimum requirement for any technology and does not prove they are ready to scale up to meet the market needs. The Indian Tb market will be hard to break into, meaningful sales may be years away.
I can`t get a feel for their strategy for their hepatitis C assay, this seems to still be at the development phase. Ads for "IL28" - I can`t find out what on earth this is for! Can someone enlighten me?
Share placing coming up and clear concerns about future funding have once again put me off investing.
I will continue to watch this disaster unfold. Very sad!
Azzi
Posted at 28/10/2015 15:32 by azzi
Unfortunately I have read the briefing note a few times now and believe they have some very deep problems with the flagship technology right now. I understand the care needed to message the city, however in this instance you don`t have to read too much between the lines to recognise that EHP will need more time and more cash to get themselves back on track. In fairness to the interim CEO, he appears to have made some honest remarks which is refreshing to see.
Posted at 14/8/2015 14:16 by azzi
Ghost, I have been an EHP supporter for years but I clearly gauged the prospect incorrectly - my mistake. Through my own findings and conclusions I have decided not to re-invest, I may well be wrong again, however I have made my decision.
End.
Posted at 14/8/2015 08:56 by azzi
Yes there are some significant differences - I do not know the pricing strategy employed by EHP. As I mentioned , my concern is whether the EHP technology is really proving itself in the field. I anticipated a raft of positive news flow at this time, maybe it is too soon, however the share price decline and sudden departure of the CEO isn`t positive.
Posted at 14/8/2015 08:42 by the ghost who walks
From your source azzi: Some concerns have been raised about the Xpert MTB/RIF, including minor operational issues and cost. The concessional price for a GeneXpert system is currently USD 17,000 for a four module instrument.
Posted at 14/8/2015 07:34 by azzi
Ghost, I should add that I invested in EHP several years ago. I believed the claims and the story. However, as you will see, even a limited amount of research highlights that EHP are playing in an increasingly crowded market for molecular biology MTB testing. My big, big,worry is that genedrive is not performing as expected.
Posted at 14/8/2015 07:21 by azzi
Ghost - Well to start with Luminex/Cepheid and GenXpert, these received WHO approval for Tb in 2010. Simply search "GeneXpert MTB/RIF" in Wikipedia for starters - I assume all investors conduct such searches as a matter of routine.
You will see that it is a direct competitor to EHP - sure there are differences but their technology has been in the market for nearly 5 years already - there is nothing novel about MTB/RIF testing!
Once you have researched some of the valuable references cited, take a look at the WHO site and search under TB and you will find many more companies playing in the same field - it should be an eye opener.
Posted at 13/8/2015 16:30 by the ghost who walks
Aside, could you share the names of competitors which are you say leaving genedrive behind so I can look into them, or post your full research ideally. Thanks
Posted at 12/8/2015 08:19 by azzi
I still monitor EHP after selling out at a loss some months ago. I stated that something wasn`t quite right with the company, I think recent events and the share price confirms this. As I have watched the decline in the sp, I have been doing some digging to find out what the prospects of the flagship product, Genedrive, really is. After all there could still be a chance to re-invest for a profit!
Unfortunately I am concluding that Genedrive is just another testing platform among an ever growing battery of molecular diagnostic devices. I worry that problems with the technology (as mentioned in Mathew Walls updates over the past 18 months)indicate fundamental weaknesses with both performance and reliability. This would explain the non existing take up in India so far. We were led to believe that Genedrive was a "disruptive" technology that would transform point of care testing - sorry, but I think EHP are being left behind, their competitors in the field are possibly years ahead of them, yet still those competitors struggle to gain traction in India. Possibly we are missing something - we know TB is endemic in parts of India, the existing testing regimes prove this, however, do the government have the resources to fund the best treatments for all those affected? I have it on good authority that they don`t. So what real benefits does a rapid test provide in India? I am applying this rationale to many other models globally and coming up with the same conclusion.
I thinks Bigmans atatement, "the Emperors new clothes" sums it up.
My recent and current searches on EPH have found nothing positive at all at a time when I would argue positive news flow should be accelerating.
I have followed the company for years and will continue to do so. however, no more green from me.
Azzi
Posted at 23/4/2015 08:42 by azzi
As I said before, I am genuinely pleased for EHP. However the news appears to have been priced in. I will watch how the story unfolds, the Indian market may not bee that easy to crack, EHP already have competitors providing exactly the same assay for Tb in India. Still todays news is a crucial step forward.
Epistem share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock